Table 1.
Autoimmune/autoinflammatory syndrome (ASIA) induced by COVID-19 vaccine N = 36
| Autoimmune disease | Number of patients | Vaccines | Autoantibodies |
|---|---|---|---|
| Neurologic | |||
| Guillain-Barré syndrome | 10 |
Sinovac 1 Sputnik 1 AstraZeneca 8 |
ANA = 1 Anti Ro = 2 RF = 3 |
| Optical neuromyelitis | 5 |
Sputnik 2 AstraZeneca 1 Moderna 1 Pfizer 1 |
AQP4 = 2 |
| Transverse myelitis | 4 |
Sputnik 1 AstraZeneca 3 |
ANA = 1 Anti Ro = 1 |
| Autoimmune encephalitis | 3 |
AstraZeneca 2 Moderna 1 |
Anti NMD = 2 Anti GABA = 1 |
| Sensory neuropathy | 2 |
Johnson & Johnson 1 AstraZeneca 1 |
ANA = 1 |
| Rheumatologic | |||
| Kawasaki vasculitis | 2 | AstraZeneca 2 |
ANA = 1 Anti Ro = 1 Coombs = 1 |
| Polyarthritis autoimmune RA | 2 | AstraZeneca 2 | RF = 1 |
| ANCA-associated vasculitis | 1 | Pfizer 1 | ANCA = 1 |
| Endrocrinologic | |||
| Graves’ disease | 2 | Pfizer 2 |
Anti TSI = 1 ANA = 1 |
| Subacute thyroiditis | 2 |
Sputnik 1 AstraZeneca 1 |
Anti TPO = 2 |
| Hematologic | |||
| Vaccine-induced immune thrombocytopenia | 3 |
AstraZeneca 2 Pfizer 1 |
IgM aCL |
ANA, antinuclear antibodies; RF, rheumatoid factor; Anti AQP4, ; Anti-Aquaporin 4 antibody , Anti NMDA, N-methyl-d-aspartate; Anti GABA, gamma-aminobutyric acid; TSI, thyroid-stimulating immunoglobulin; Anti TPO, antithyroid peroxidase; IgM aCL, IgM anti cardiolipin antibodies